BRAF mutational status is associated with survival outcomes in locally advanced resectable and metastatic NSCLC.

doi:10.1016/j.lungcan.2024.107865

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Community

Back to search

Article

BRAF mutational status is associated with survival outcomes in locally advanced resectable and metastatic NSCLC.

Lung cancer (Amsterdam, Netherlands) - 1 Aug 2024

Provencio Mariano, Robado de Lope Lucía, Serna-Blasco Roberto, Nadal Ernest, Diz Tain Pilar, Massuti Bartomeu, González-Larriba José Luis, Insa Amelia, Sánchez-Hernández Alfredo, Casal-Rubio Joaquín, García-Campelo Rosario, Sequero López Silvia, Rogado Jacobo, Martínez-Martí Alex, Bosch-Barrera Joaquim, Bernabé Reyes, Vázquez Estévez Sergio, Ponce Santiago, de Castro Javier, Coves Sarto Juan, Reguart Noemí, Dómine Manuel, Aguilar Andrés, Majem Margarita, Estival Anna, Peña Cabia Silvia, López Martín Ana, Sala González María Ángeles, Cobo Manuel, Camps Carlos, Barneto Isidoro, Calvo Virginia, Collazo-Lorduy Ana, Cruz-Bermúdez Alberto, Romero Atocha

Abstract excerpt

BACKGROUND: Immunotherapy-based treatments have demonstrated high efficacy in patients with advanced and locally advanced non-small-cell lung cancer (NSCLC). BRAF mutations affect a small but significant fraction of NSCLC. The efficacy of these therapies in this subgroup of patients is unknown. MATERIALS AND METHODS: Plasma and tissue samples from 116 resectable stage IIIA/B NSCLC patients, included in NADIM and...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Biomarkers, Tumor

Share to Carcinoma, Non-Small-Cell Lung

Share to Immunotherapy

Share to Lung Neoplasms

Share to Neoplasm Metastasis

Share to Neoplasm Staging

Share to Prognosis

Share to Proto-Oncogene Proteins B-raf

Source

Open in PubMed

Identifiers

PMID: 38945004
DOI: 10.1016/j.lungcan.2024.107865

Genes

BRAF

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 9 closest

BRAF mutational status is associated with survival outcomes in locally advanced resectable and metastatic NSCLC.PMID 38945004Read ↗

Treatment outcome of NSCLC patients with BRAF mutations: a retrospective, multicentre analysis within the national Network Genomic Medicine (nNGM) Lung Cancer in GermanySemantic proximity Read ↗

The impact of oncogenic driver mutations on neoadjuvant immunotherapy outcomes in patients with resectable non-small cell lung cancer.Semantic proximity Read ↗

BRAF mutations and BRAF mutation functional class have no negative impact on the clinical outcome of advanced NSCLC and associate with susceptibility to immunotherapy.Semantic proximity Read ↗

BRAF mutation predicts survival after immunotherapy across multiple cancer types.Semantic proximity Read ↗

Treatment Sequences in BRAF-V600-Mutated NSCLC: First-Line Targeted Therapy Versus First-Line (Chemo-) Immunotherapy.Semantic proximity Read ↗

A large-scale, multicenter characterization of BRAF G469V/A-mutant non-small cell lung cancer.Semantic proximity Read ↗

BRAF Mutant Lung Cancer: Programmed Death Ligand 1 Expression, Tumor Mutational Burden, Microsatellite Instability Status, and Response to Immune Check-Point Inhibitors.Semantic proximity Read ↗

Lung Cancer Driven by BRAFG469V Mutation Is Targetable by EGFR Kinase Inhibitors.Semantic proximity Read ↗

Neoadjuvant Chemoimmunotherapy in Patients with Resectable Non-small Cell Lung Cancer.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.